The hypoparathyroidism market is expected to grow by factors like an increase in the patient pool, and expected entry of emerging therapies.
New York, USA, Feb. 05, 2024 (GLOBE NEWSWIRE) — Hypoparathyroidism Market is Expected to Exhibit Impressive Growth by 2032, Assesses DelveInsight | Leading Companies Developing Therapies – Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics
The hypoparathyroidism market is expected to grow due to factors like an increase in the patient pool, and the expected entry of emerging therapies.
DelveInsight’s Hypoparathyroidism Market Insights report includes a comprehensive understanding of current treatment practices, hypoparathyroidism emerging drugs, market share of individual therapies, and current and forecasted hypoparathyroidism market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Hypoparathyroidism Market Report
- According to DelveInsight’s analysis, the market size for hypoparathyroidism reached USD 250 million in 2022 across the 7MM and is expected to grow with a significant CAGR by 2032.
- DelveInsight’s analysis reveals that the overall prevalent population of hypoparathyroidism in the 7MM was reported as 284K in 2022.
- Prominent companies working in the domain of hypoparathyroidism, including Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics, and others, are actively working on innovative drugs for hypoparathyroidism. These novel hypoparathyroidism therapies are anticipated to enter the hypoparathyroidism market in the forecast period and are expected to change the market.
- Some of the key therapies for hypoparathyroidism treatment include TRANSCON PTH (palopegteriparatide), Eneboparatide (AZP-3601), Encaleret (BBP-305/CLTX-305), and others.
Discover which therapies are expected to grab the hypoparathyroidism market share @ Hypoparathyroidism Market Report
Hypoparathyroidism is characterized by low levels of calcium and high levels of phosphorus due to insufficient secretion or action of parathyroid hormone (PTH). This condition may manifest as part of an autoimmune disorder affecting multiple glands or as a complex congenital defect, such as in the autosomal dominant DiGeorge syndrome or hypoparathyroidism, deafness, and renal dysplasia (HDR) syndromes. The primary cause of hypoparathyroidism is often the accidental injury or removal of all four parathyroid glands, which can occur during thyroid surgery. Some individuals are also born without these glands, and in certain cases, the glands may not function properly for reasons that are not well understood. Symptoms of hypocalcemia include sensations of numbness and tingling around the mouth, neurocognitive deficits, weakness, and spasms in the muscles of the hands and feet. Severe complications, such as life-threatening cardiac arrhythmias, laryngeal spasms, tetany, and seizures, can also arise from hypocalcemia in cases of hypoparathyroidism.
Hypoparathyroidism Epidemiology Segmentation
The hypoparathyroidism epidemiology section provides insights into the historical and current hypoparathyroidism patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The hypoparathyroidism market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Prevalent Cases of Hypoparathyroidism
- Diagnosed Prevalent Cases of Hypoparathyroidism
- Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism
- Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism
- Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism
- Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism
Download the report to understand which factors are driving hypoparathyroidism epidemiology trends @ Hypoparathyroidism Epidemiological Insights
Hypoparathyroidism Treatment Market
Conventional management of chronic hypoparathyroidism typically involves the administration of additional calcium in conjunction with active vitamin D metabolites. When administering calcium supplements, it is crucial to note that many formulations indicate the weight of the entire calcium salt. However, healthcare providers must be mindful of the actual elemental calcium content. Various categories of medications, such as human parathyroid hormone (PTH), calcium-sensing receptor antagonists, hormone replacement therapy, and others, are accessible in the market for treating this condition.
Historically, patients were subjected to higher-than-normal doses of vitamin D (ergocalciferol or cholecalciferol). However, the current recommendation favors the use of physiological doses of 1,25-dihydroxy vitamin D (calcitriol) in conjunction with supplementary calcium. Although the majority of hypoparathyroidism cases are still managed with calcitriol and calcium, a notable development occurred in January 2015 when the FDA approved Natpara. This entails daily subcutaneous injections of recombinant human PTH (1–84) and is intended for specific patients whose conditions prove challenging to control with more traditional therapeutic approaches.
Natpara received Orphan Drug designation for treating hypoparathyroidism from the FDA in 2007 and from the EC in 2014. It was made available in the market through a Risk Evaluation and Mitigation Strategy (REMS) Program and a limited network of specialty pharmacies. The drug was launched in the US market in April 2015 and held exclusive approval for hypoparathyroidism patients until September 2019. However, Takeda issued a US recall of Natpara in September 2019 due to the discovery of small particles of rubber in some samples of the solution, linked to the reusable injection system. This recall was initiated by Takeda to ensure patient safety. Healthcare professionals were notified to closely monitor patients’ calcium levels because a sudden discontinuation of Natpara could lead to a rapid drop in calcium levels, potentially causing severe health problems.
Learn more about the FDA-approved drugs for hypoparathyroidism @ Drugs for Hypoparathyroidism Treatment
Key Hypoparathyroidism Therapies and Companies
- TRANSCON PTH (palopegteriparatide): Ascendis Pharma
- Eneboparatide (AZP-3601): Amolyt Pharma
- Encaleret (BBP-305/CLTX-305): Bridgebio/Calcilytix Therapeutics
To know more about hypoparathyroidism clinical trials, visit @ Hypoparathyroidism Treatment Drugs
The hypoparathyroidism market dynamics are anticipated to change in the coming years. Based on the route of administration, the parenteral method is anticipated to be the fastest-growing segment compared to oral methods. The extensive radiation treatment for cancer on the neck or face, coupled with new technological advancements for treating hypoparathyroidism, is poised to further enhance the overall development of the hypoparathyroidism treatment market. Calcium supplements are likely to maintain their status as the most preferred drug class in the future, accounting for approximately 38% of the market share. Additionally, PTH is expected to exhibit a substantial growth rate. The sales of hypoparathyroidism treatment drugs through retail pharmacies are projected to generate maximum revenue, followed by hospital pharmacies.
Furthermore, many potential therapies are being investigated for the treatment of hypoparathyroidism, and it is safe to predict that the treatment space will significantly impact the hypoparathyroidism market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the hypoparathyroidism market in the 7MM.
However, several factors may impede the growth of the hypoparathyroidism market. There exists an unmet need for efficacious and safe treatment of secondary hyperparathyroidism (SHPT) in non-dialysis CKD patients, supported by evidence indicating the necessity for early intervention in SHPT management. This timely treatment approach could significantly influence medication usage and mitigate the risk of uncontrolled PTH during dialysis. The hypoparathyroidism market landscape is further complicated by already available off-labeled drugs, which pose formidable competition to emerging treatments. However, factors such as lengthy clinical approval cycles and trials not aligning with treatment guidelines established by regulatory authorities are anticipated to impede the hypoparathyroidism market’’s growth.
Moreover, hypoparathyroidism treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the hypoparathyroidism market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the hypoparathyroidism market growth.
|Hypoparathyroidism Report Metrics
|Hypoparathyroidism Report Coverage
|7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
|Hypoparathyroidism Market Size in 2022
|USD 250 Million
|Key Hypoparathyroidism Companies
|Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics, and others
|Key Hypoparathyroidism Therapies
|TRANSCON PTH (palopegteriparatide), Eneboparatide (AZP-3601), Encaleret (BBP-305/CLTX-305), and others
Scope of the Hypoparathyroidism Market Report
- Hypoparathyroidism Therapeutic Assessment: Hypoparathyroidism current marketed and emerging therapies
- Hypoparathyroidism Market Dynamics: Attribute Analysis of Emerging Hypoparathyroidism Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Hypoparathyroidism Market Access and Reimbursement
Discover more about hypoparathyroidism drugs in development @ Hypoparathyroidism Clinical Trials
Table of Contents
|Hypoparathyroidism Market Key Insights
|Hypoparathyroidism Market Report Introduction
|Hypoparathyroidism Market Overview at a Glance
|Hypoparathyroidism Market Executive Summary
|Disease Background and Overview
|Hypoparathyroidism Treatment and Management
|Hypoparathyroidism Epidemiology and Patient Population
|Hypoparathyroidism Marketed Drugs
|Hypoparathyroidism Emerging Drugs
|Seven Major Hypoparathyroidism Market Analysis
|Hypoparathyroidism Market Outlook
|Potential of Current and Emerging Therapies
Hypoparathyroidism Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted hypoparathyroidism epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Hypoparathyroidism Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypoparathyroidism companies, including Ascendis Pharma, Calcilytix Therapeutics, Amolyt Pharma, AEterna Zentaris Inc, Entera Bio, Sigilon Therapeutics, ProLynx, Extend Biosciences, among others.
Hyperparathyroidism Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hyperparathyroidism companies including Vidasym Inc., Mitsubishi Tanabe Pharma, Shanghai Hengrui Pharmaceutical, among others.
Secondary Hyperparathyroidism Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key secondary hyperparathyroidism companies, including Jiangsu Hengrui Medicine Co Ltd, Mitsubishi Tanabe Pharma Corp, OPKO Health Inc, Shaanxi Micot Technology Co Ltd, Amgen Inc, Cinkate Corp, Novadiol Inc, Scohia Pharma Inc, TaiRx Inc, Vidasym Inc., among others.
Hyperparathyroidism Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hyperparathyroidism companies, including Vidasym Inc., Mitsubishi Tanabe Pharma, Shanghai Hengrui Pharmaceutical, among others.
Secondary Hyperparathyroidism Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key secondary hyperparathyroidism companies, including Jiangsu Hengrui Medicine Co Ltd, Mitsubishi Tanabe Pharma Corp, OPKO Health Inc, Shaanxi Micot Technology Co Ltd, Amgen Inc, Cinkate Corp, Novadiol Inc, Scohia Pharma Inc, TaiRx Inc, Vidasym Inc., among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
CONTACT: Contact Us Shruti Thakur firstname.lastname@example.org +91-9650213330 www.delveinsight.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.